Nektar Therapeutics - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
NKTR Nasdaq 8731 http://www.nektar.com 22.22 Stock Down -0.21

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Nektar Therapeutics

Nektar Therapeutics Appoints Biotechnology Executive Jeff Ajer as New Board Member - Sep 21st, 2017 2:30 pm
Should You Buy Nektar Therapeutics (NKTR) Now? - Sep 21st, 2017 1:15 pm
Nektar Therapeutics Announces Seven Abstracts Accepted for Presentation at 2017 Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting - Sep 20th, 2017 4:00 am
ETFs with exposure to Nektar Therapeutics : September 13, 2017 - Sep 13th, 2017 5:11 pm
Nektar (NKTR) Starts PROPEL Combo Study for Cancer Candidate - Sep 13th, 2017 9:32 am
Nektar Therapeutics Initiates PROPEL Clinical Study to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with TECENTRIQ® (atezolizumab) or KEYTRUDA® (pembrolizumab) - Sep 12th, 2017 7:00 am
See what the IHS Markit Score report has to say about Nektar Therapeutics. - Sep 12th, 2017 6:06 am
Nektar Therapeutics :NKTR-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017 - Sep 11th, 2017 12:06 pm
Surging Earnings Estimates Signal Good News for Nektar (NKTR) - Sep 8th, 2017 7:00 am
Nektar Therapeutics Presents Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2017 PAINWeek® - Sep 6th, 2017 4:00 pm
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2017 Morgan Stanley Global Healthcare Conference in New York City - Sep 6th, 2017 7:15 am
Nektar Therapeutics breached its 50 day moving average in a Bullish Manner : NKTR-US : September 1, 2017 - Sep 1st, 2017 8:03 am
Today's Research Reports on Trending Tickers: Nektar Therapeutics and Ionis Pharmaceuticals Inc. - Sep 1st, 2017 6:00 am
Nektar Therapeutics to Present Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at PAINWeek® - Aug 30th, 2017 7:00 am
Nektar Therapeutics Earns Relative Strength Rating Upgrade; Hits Key Benchmark - Aug 29th, 2017 1:00 am
Nektar Therapeutics – Value Analysis (NASDAQ:NKTR) : August 17, 2017 - Aug 16th, 2017 7:41 pm
Are Options Traders Betting on a Big Move in Nektar (NKTR) Stock? - Aug 16th, 2017 6:31 am